Skip to main content
Breast Cancer
Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR-Positive, HER2-Negative, PIK3CA Mutation–Positive Breast Cancer
Read More
Breast Cancer
Updates on Endocrine Therapy for Metastatic Breast Cancer
Read More
Breast Cancer
Patient-Reported Outcomes from a Phase 3 Trial in Premenopausal Patients with ER-Positive, HER2-Negative, Lymph Node–Positive Breast Cancer
Read More
Breast Cancer
Checkpoint Inhibitor Therapy for Metastatic Triple-Negative Breast Cancer
Read More
Breast Cancer, Antibody–Drug Conjugates
Emerging Immunotherapy Combination Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody–Drug Conjugates, and Bispecific Antibodies
Read More
Breast Cancer
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: An Overview of Clinical Management and Potential Toxicities
Read More
Breast Cancer
SASCIA Phase 3 Trial Evaluating Sacituzumab Govitecan in Patients with Primary HER2-Negative Breast Cancer with High Relapse Risk
Read More
Breast Cancer
Trastuzumab Deruxtecan Granted Breakthrough Therapy Designation in United States for Patients with HER2-Positive Metastatic Breast Cancer Treated with ≥1 Previous Anti-HER2–Based Regimens
Read More
Breast Cancer, Antibody–Drug Conjugates
New Antibody–Drug Conjugates in Breast Cancer
Read More
Breast Cancer
Advancements in Targeted Therapy and Immunotherapy for Human Breast Cancer
Read More
Page 64 of 199
Results 631 - 640 of 1986